Document is current
Any future updates will be listed below
-
Authors
D´Arrigo, Daniele
Park, Kyong-Su
Lässer, Cecilia
Sigalas, Georgios Panagiotis
Symonds, Emma
Urzí, Ornella
Locatelli, Camilla
Olofsson Bagge, Roger
Lötvall, Jan
Crescitelli, Rossella
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Received: 11 January 2026
Accepted: 7 May 2026
First Online: 21 May 2026
Declarations
:
: Ethics approval was granted by the Regional Ethical Review Board at the University of Gothenburg, Sweden (Dnr #096 − 12 and 995 − 16). The patients provided written informed consent.
: All authors read and approved the final manuscript.
: RC, KSP, CL, and JL have developed multiple EV-associated patents for putative clinical utilization. RC, KSP, CL, and JL own equity in Exocure Sweden AB. ROB has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag), SkyLineDx and NeraCare GmbH, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Cansr.com, Merck Sharp & Dohme (MSD), Novartis, and Roche and Sanofi Genzyme, and is a shareholder in SATMEG Ventures AB.
